Quest Diagnostics (DGX) Beats, Raises and Plunges, BofA Securities Frames the Covid Testing Landscape
Tweet Send to a Friend
BofA Securities analyst Derik de Bruin reiterated a Buy rating and $174.00 price target on Quest Diagnostics (NYSE: DGX) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
